Acrivon Therapeutics announced data from two posters that the company presented at the American Association for Cancer Research, AACR, Annual Meeting. “Our data at AACR illustrate several of the broad capabilities of our AP3 platform and the power of employing this precision proteomics-based approach in both drug discovery and drug development,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. “Uniquely enabled by AP3, we designed a selective and potent dual inhibitor of both WEE1 and PKMYT1, ACR-2316, designed for potent single agent activity. We presented preclinical data showing its superior activity versus benchmark WEE1 and PKMYT1 single-agent inhibitors in multiple cancer models and look forward to advancing this compound into the clinic. Additionally at AACR, we presented data on the underlying mechanisms that drive resistance to treatment with ACR-368, which were discovered through AP3 profiling, and which led to the identification of ULDG as a way to sensitize resistant ovarian cancer cells to ACR-368. These actionable insights highlight Acrivon’s differentiated approach to drug development.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
- Acrivon Therapeutics Secures $130M for Drug Development Expansion
- Acrivon to sell 8.24M shares at $8.50 in private placement financing
- Ladenburg ‘more suspicious’ about Acrivon upcoming data, cuts target
- Acrivon Therapeutics price target lowered to $21 from $25 at Oppenheimer